Genetic vasopressin 1b receptor variance in overweight and diabetes mellitus

Objective Recently, imbalance in the vasopressin (AVP) system, measured as elevated levels of copeptin (the C-terminal part of the AVP pro-hormone) in plasma, was linked to the development of abdominal obesity and diabetes mellitus (DM). Here, we aim to investigate if the genetic variation of the human AVP receptor 1b gene (AVPR1B) is associated with measures of obesity and DM. Design Malmö Diet and Cancer study (MDC) is a population-based prospective cohort examined 1991–1996. Methods Four tag single nucleotide polymorphisms (SNPs: rs35810727, rs28373064, rs35439639, rs35608965) of AVPR1B were genotyped in the cardiovascular cohort (n=6103) of MDC (MDC-CC) and associated with measures of obesity and DM. Significant SNPs were replicated in another 24 344 MDC individuals (MDC replication cohort). Results In MDC-CC, the major allele of rs35810727 was associated with elevated BMI (β-coefficient±s.e.m.; 0.30±0.14, P=0.03) and waist (0.78±0.36, P=0.03) after age and gender adjustment. The association with BMI was replicated in the MDC replication cohort (0.21±0.07, P=0.003), whereas that with waist was not significant. In MDC-CC there was no association between the major allele of rs35810727 and DM, but in the complete MDC cohort (n=30 447) the major allele of rs35810727 was associated with DM (OR (95% CI); 1.10 (1.00–1.20), P=0.04). Conclusions Genetic variance of AVPR1B contributes to overweight. Furthermore, our data indicate a link between AVPR1B variance and DM development. Our data point at a relationship between the disturbance of the pharmacologically modifiable AVP system and the body weight regulation.

[1]  O. Melander,et al.  Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort , 2013, International Journal of Obesity.

[2]  R. Gans,et al.  Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study , 2012, Diabetologia.

[3]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[4]  O. Melander,et al.  Plasma copeptin, a unifying factor behind the metabolic syndrome. , 2011, The Journal of clinical endocrinology and metabolism.

[5]  C. Wanner,et al.  Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. , 2011, Journal of the American Society of Nephrology : JASN.

[6]  A. Siani,et al.  Heritability of body weight: moving beyond genetics. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[7]  L. Groop,et al.  Plasma Copeptin and the Risk of Diabetes Mellitus , 2010, Circulation.

[8]  Y. Tabara,et al.  Vasopressin V1a Receptor Polymorphism and Interval Walking Training Effects in Middle-Aged and Older People , 2010, Hypertension.

[9]  D. Mikhailidis,et al.  Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  I. Kullo,et al.  Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. , 2009, The Journal of clinical endocrinology and metabolism.

[11]  O. Melander,et al.  Relation between human vasopressin 1a gene variance, fat intake, and diabetes. , 2009, The American journal of clinical nutrition.

[12]  K. Narayan,et al.  Clinical risk factors, DNA variants, and the development of type 2 diabetes. , 2009, The New England journal of medicine.

[13]  Ellen Kampman,et al.  Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity , 2009, Nature Genetics.

[14]  Björn Eliasson,et al.  Risk Prediction of Cardiovascular Disease in Type 2 Diabetes , 2008, Diabetes Care.

[15]  G. Tsujimoto,et al.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor , 2007, The Journal of physiology.

[16]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[17]  G. Berglund,et al.  Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome on Incidence of Cardiovascular Events Among Middle-Aged Nondiabetic Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Tanoue,et al.  Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. , 2007, Endocrinology.

[19]  F. Endo,et al.  Hypermetabolism of fat in V1a vasopressin receptor knockout mice. , 2007, Molecular endocrinology.

[20]  J. Struck,et al.  Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. , 2006, Clinical chemistry.

[21]  G. Berglund,et al.  Blood Pressure Control and Risk of Stroke: A Population-Based Prospective Cohort Study , 2005, Stroke.

[22]  G. Tsujimoto,et al.  The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. , 2004, The Journal of clinical investigation.

[23]  L. Groop,et al.  Classifying diabetes according to the new WHO clinical stages , 2004, European Journal of Epidemiology.

[24]  J. Granton,et al.  Science Review: Vasopressin and the cardiovascular system part 1 – receptor physiology , 2003, Critical care.

[25]  S. Ralston,et al.  Single nucleotide polymorphism detection: allelic discrimination using TaqMan. , 2002, Psychiatric genetics.

[26]  S. Yibchok-anun,et al.  Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. , 2002, Metabolism: clinical and experimental.

[27]  Russell Senior,et al.  A Population-Based Prospective Cohort Study of Personal Exposure to Magnetic Fields during Pregnancy and the Risk of Miscarriage , 2002, Epidemiology.

[28]  G. Aguilera,et al.  Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. , 1998, Endocrinology.

[29]  G A Colditz,et al.  Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men , 1994, Diabetes Care.

[30]  G. Berglund,et al.  Design and feasibility , 1993 .

[31]  G. Berglund,et al.  The Malmo Diet and Cancer Study. Design and feasibility. , 1993, Journal of internal medicine.

[32]  Michael J. Brownstein,et al.  Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus , 1992, Nature.

[33]  J. Filep,et al.  Mechanism of vasopressin-induced platelet aggregation. , 1987, Thrombosis research.

[34]  B. Berkowitz,et al.  Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. , 1986, The Journal of pharmacology and experimental therapeutics.

[35]  S. Keppens,et al.  The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. , 1979, Biochimica et biophysica acta.

[36]  L. Rodrigues,et al.  Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. , 1978, The Biochemical journal.